Symbol="TGTX"
AssetType="Common Stock"
Name="TG Therapeutics Inc"
Description="TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York."
CIK="1001316"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1579230000"
EBITDA="-168442000"
PERatio="None"
PEGRatio="0"
BookValue="0.287"
DividendPerShare="0"
DividendYield="0"
EPS="-1.24"
RevenuePerShareTTM="0.174"
ProfitMargin="0"
OperatingMarginTTM="-7.01"
ReturnOnAssetsTTM="-0.446"
ReturnOnEquityTTM="-2.073"
RevenueTTM="24052000"
GrossProfitTTM="2520000"
DilutedEPSTTM="-1.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="26.06"
AnalystTargetPrice="28.94"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="249.27"
PriceToBookRatio="10.88"
EVToRevenue="198.82"
EVToEBITDA="-4.349"
Beta="2.014"
num_52WeekHigh="35.67"
num_52WeekLow="4.86"
num_50DayMovingAverage="17.5"
num_200DayMovingAverage="17.52"
SharesOutstanding="150978000"
DividendDate="None"
ExDividendDate="None"
symbol="TGTX"
open="10.50"
high="10.84"
low="10.22"
price="10.59"
volume="2934105.00"
latest_trading_day="2023-08-30"
previous_close="10.46"
change="0.13"
change_percent="1.2428%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="32"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="68"
Volume_recent_avg="4801691"
Change_recent_avg="0.02"
Delta_recent_avg="1.44"
Variance_recent_avg="0.72"
Change_ratio_recent_avg="-0.01"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="68"
Aroon_momentum_negative="32"
image_negative_thumbnail_id_1="1138"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0171.jpeg"
image_negative_thumbnail_id_2="1103"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0136.jpeg"
image_neutral_thumbnail_id_1="585"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_neutral_thumbnail_id_2="534"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0065.jpeg"
image_positive_thumbnail_id_1="991"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0153.jpeg"
image_positive_thumbnail_id_2="615"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0093.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
